Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bno8
- Development stage
- Preclinical
- Lead developer
- L&L Biopharma
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics
01
Overview
Bno8 is an investigational oncolytic virus therapy being developed by L & L Biopharma (also known as Lingnuo Pharmaceutical) for the treatment of cancers that have developed resistance to anti-PD-1/PD-L1 immune checkpoint inhibitors. As an oncolytic virus, Bno8 is engineered to selectively infect, replicate within, and lyse malignant cells, thereby releasing tumor-associated antigens and promoting a pro-inflammatory tumor microenvironment. This mechanism is intended to stimulate a systemic anti-tumor immune response and potentially re-sensitize "cold" or resistant tumors to checkpoint inhibition. Bno8 is currently an early-stage asset within the company's immuno-oncology pipeline.
Beyond the preview
Go deeper on Bno8.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bno8.